




U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/088 (07-08)

Approved for use through 09/30/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 122B/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/618,299
		Filing Date	July 11, 2003
		First Named Inventor	James G. Barsoum
		Art Unit	1633
		Examiner Name	Robert M. Kelly
		Attorney Docket Number	2159.0830001/EJH/SAS
Sheet	1	of	3

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
MLK	NPL1	Brunner, K.T., <i>et al.</i> , "Blood Clearance of P ₃₂ -Labeled Vesicular Stomatitis and Newcastle Disease Viruses by the Reticuloendothelial System in Mice," <i>J. Immunol.</i> , 85:99-105, American Association of Immunologists (1960)	
	NPL2	Cai, P., <i>et al.</i> , "Methyl palmitate: Inhibitor of phagocytosis in primary rat Kupffer cells," <i>Toxicol.</i> 210:197-204, Elsevier Ireland Ltd. (June 2005)	
	NPL3	Dachs, G.U., <i>et al.</i> , "Targeting Gene Therapy to Cancer: a Review," <i>Oncol. Res.</i> 9:313-325, Cognizant Communication Corporation (1997)	
	NPL4	Fahimi, H.D., "The Fine Structural Localization of Endogenous and Exogenous Peroxidase Activity in Kupffer Cells of Rat Liver," <i>J. Cell Biol.</i> 47:247-262, Rockefeller University Press (1970)	
	NPL5	Kim, A., <i>et al.</i> , "Uptake of Viruses by Kupffer Cells Isolated from Human Liver," <i>Lancet North Am. Ed.</i> 2:585-586, Lancet Publishing Group (1980)	
	NPL6	Kolb-Bachofen, V., "Uptake of Toxic Silica Particles by Isolated Rat Liver Macrophages (Kupffer Cells) Is Receptor Mediated and Can Be Blocked by Competition," <i>J. Clin. Invest.</i> 90:1819-1824, The American Society for Clinical Investigation, Inc. (1992)	
	NPL7	Laurent, N., <i>et al.</i> , "Uptake by rat liver and intracellular fate of plasmid DNA complexed with poly-L-lysine or poly-D-lysine," <i>FEBS Lett.</i> 443:61-65, Federation of European Biochemical Societies (1999)	
	NPL8	Kuzmin, A.I., <i>et al.</i> , "Macrophage depletion increases the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo," <i>Gene Ther.</i> 4:309-316, Stockton Press (1997)	
V	NPL9	Marianneau, P., <i>et al.</i> , "Infection of Primary Cultures of Human Kupffer Cells by Dengue Virus: No Viral Progeny Synthesis, but Cytokine Production Is Evident," <i>J. Virol.</i> 73:5201-5206, American Society for Microbiology (1999)	
MLK	NPL10	McCuskey, R.S., <i>et al.</i> , "Kupffer Cell Function in Host Defense," <i>Rev. Infect. Dis.</i> 9:S616-S619, The University of Chicago (1987)	

Examiner Signature	Robert M. Kelly	Date Considered	5/18/07
--------------------	-----------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/618,299
				Filing Date	July 11, 2003
				First Named Inventor	James G. Barsoum
				Art Unit	1633
				Examiner Name	Robert M. Kelly
Sheet	2	of	3	Attorney Docket Number	2159.0830001/EJH/SAS

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
AMK	NPL11	Miller, N., and Vile, R., "Targeted vectors for gene therapy," <i>FASEB J.</i> 9:190-199, The Federation of American Societies for Experimental Biology (1995)	
	NPL12	Mogensen, S.C., "Macrophages and Age-Dependent Resistance to Hepatitis Induced by Herpes Simplex Virus Type 2 in Mice," <i>Infect. Immun.</i> 19:46-50, American Society for Microbiology (1978)	
	NPL13	Rentsch, M., <i>et al.</i> , "Benefit of Kupffer cell modulation with glycine versus Kupffer cell depletion after liver transplantation in the rat: effects on postischemic reperfusion injury, apoptotic cell death graft regeneration and survival," <i>Transpl. Int.</i> 18:1079-1089, European Society for Organ Transplantation (September 2005)	
	NPL14	Rubin, D.H., <i>et al.</i> , "Transport of Infectious Reovirus into Bile: Class II Major Histocompatibility Antigen-Bearing Cells Determine Reovirus Transport," <i>J. Virol</i> 61:3222-3226, American Society for Microbiology (1987)	
	NPL15	Selgrade, M.K., and Osborn, J.E., "Role of Macrophages in Resistance to Murine Cytomegalovirus," <i>Infect. Immun.</i> 10:1383-1390, American Society for Microbiology (1974)	
	NPL16	van Til, N.P., <i>et al.</i> , "Kupffer Cells and Not Liver Sinusoidal Endothelial Cells Prevent Lentiviral Transduction of Hepatocytes," <i>Mol. Ther.</i> 11:26-34, The American Society of Gene Therapy (January 2005)	
	NPL17	Wake, K., <i>et al.</i> , "Cell Biology and Kinetics of Kupffer Cells in the Liver," <i>Int. Rev. Cytol.</i> 118:173-229, Academic Press, Inc. (1989)	
AMK	NPL18	Zenilman, M.E., <i>et al.</i> , "Use of Ricin A-Chain to Selectively Deplete Kupffer Cells," <i>J. Surg. Res.</i> 45:82-89, Academic Press, Inc. (1988)	

582847v1

Examiner Signature		Date Considered	5/18/07
--------------------	-------------------------------------------------------------------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/618,299		
		Filing Date	July 11, 2003		
		First Named Inventor	BARSOUM, James G.		
		Art Unit	1633		
		Examiner Name	KELLY, Robert M.		
Sheet	3	of	3	Attorney Docket Number	2159.0830001/EJH/SAS

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
RMK	NPL19	Leissner, P., et al., "Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism," <i>Gene Ther.</i> 8:49-57, Nature Publishing Group (January 2001)	

619160v1

Examiner Signature		Date Considered	5/18/07
-----------------------	-------------------------------------------------------------------------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.